SCHEMBL13653136

SCHEMBL13653136

CC(=O)NC1CCc2cc(C(=O)Nc3ccccc3NC(=O)OC(C)(C)C)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MITF O75030 1/20 0.43
RAB9A P51151 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
ATM Q13315 1/20 0.41
LMNA P02545 1/20 0.41
ROCK2 O75116 1/20 0.40
TRPV1 Q8NER1 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185804 0.92 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL13653133 0.89 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL13653109 0.87 PDE4A (0.39) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL13653146 0.87 MAPT (0.52) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL4184531 0.85 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL13653102 0.85 MEN1 (0.42) MEN1KMT2ARAB9A
SCHEMBL13653131 0.83 TRPV1 (0.39) PDE4APDE4BPDE4CPDE4DTAS1R3
SCHEMBL13653140 0.83 NPY1R (0.41) PDE4APDE4BPDE4CPDE4DRAB9A
SCHEMBL13653130 0.83 NAMPT (0.44) TRPV1NPY1R
SCHEMBL4180693 0.82 CA12 (0.52) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247590-A1 Indane amides BAYER PHARMACEUTICLAS CORPORATION (US) 2009-10-01 US disclosed
US-20090247590-A1 Indane amides BAYER PHARMACEUTICLAS CORPORATION (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247590-A1 Indane amides MKI67, PPIP5K2, CCNA1 CA12 3149/4885CA1 4572/4885CA2 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.